Camblong Jurgi 4

4 · SOPHiA GENETICS SA · Filed Jun 29, 2026

AI-generated summary of this filing

Updated Jun 29, 2026

SOPH CEO Jurgi Camblong Exercises Options, Sells Shares

What Happened

Jurgi Camblong, CEO of SOPHiA GENETICS SA (SOPH), exercised 31,940 stock options and sold shares across multiple transactions on June 25–26, 2026.
He exercised 31,940 options at $3.16 per share (cash paid $100,930) and sold those 31,940 shares at a weighted average of $5.84 for proceeds of $186,395. In addition he sold 18,129 shares at a weighted average of $5.73 for $103,934 and 1,373 shares at $5.70 for $7,826. Total shares sold = 51,442; total proceeds from sales ≈ $298,155.
The activity includes an acquisition (option exercise) and multiple sales; sales are often routine disposition of previously granted equity and are not by themselves a definitive signal of sentiment.

Key Details

Transaction dates: 2026-06-25 (1,373 shares sold) and 2026-06-26 (other exercises/sales). Filing date: 2026-06-29 (Form 4).
Prices/ranges: 1,373 @ $5.70; 18,129 @ weighted avg $5.73 (range $5.70–$5.78); 31,940 @ weighted avg $5.84 (range $5.80–$5.94). Exercise price: $3.16 for the 31,940 options exercised.
Shares owned after transaction (derivative holdings): holds 4,709,536 outstanding stock options across remaining grant tranches (per filing).
Footnotes of note: F1 indicates at least some trades were made pursuant to a Rule 10b5-1 trading plan; F4 confirms the options were fully vested; F2/F3 note weighted-average sale prices and provide price ranges.
Timeliness: Filed on 2026-06-29; the Form 4 reports transactions from 6/25–6/26 and was filed promptly (not indicated as late).

Context

This appears to be a typical option exercise followed by sales (a cashless-type outcome): options were exercised at $3.16 and those shares were sold at higher market prices, generating net proceeds.
The CEO still holds a large options position (4.7M+ options), meaning further exercises or sales are possible in the future.
The filing is factual disclosure of insider activity; it does not by itself explain motivations.

Form 4

Period: 2026-06-25

DirectorExecutive Chairman

Transactions

Sale
Ordinary Shares
[F1]
2026-06-25$5.70/sh−1,373$7,826→ 3,619,622 total
Sale
Ordinary Shares
[F1][F2]
2026-06-26$5.73/sh−18,129$103,934→ 3,601,493 total
Exercise/Conversion
Ordinary Shares
[F1]
2026-06-26$3.16/sh+31,940$100,930→ 3,633,433 total
Sale
Ordinary Shares
[F1][F3]
2026-06-26$5.84/sh−31,940$186,395→ 3,601,493 total
Exercise/Conversion
Share Option (Right to Buy)
[F4][F5]
2026-06-26−31,940→ 68,060 total
Exercise: $3.16Exp: 2028-11-29→ Ordinary Shares (31,940 underlying)

Footnotes (5)

[F1]Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.70 to $5.78, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.80 to $5.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The share options are fully vested and exercisable.
[F5]Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,709,536 derivative stock options across all remaining grant tranches with varying exercise prices.

Signature

/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong|2026-06-29

1 file